SG11202100307WA - T cell-antigen coupler with various construct optimizations - Google Patents
T cell-antigen coupler with various construct optimizationsInfo
- Publication number
- SG11202100307WA SG11202100307WA SG11202100307WA SG11202100307WA SG11202100307WA SG 11202100307W A SG11202100307W A SG 11202100307WA SG 11202100307W A SG11202100307W A SG 11202100307WA SG 11202100307W A SG11202100307W A SG 11202100307WA SG 11202100307W A SG11202100307W A SG 11202100307WA
- Authority
- SG
- Singapore
- Prior art keywords
- optimizations
- cell
- antigen coupler
- various construct
- construct
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 238000005457 optimization Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862699173P | 2018-07-17 | 2018-07-17 | |
US201862703037P | 2018-07-25 | 2018-07-25 | |
US201862773120P | 2018-11-29 | 2018-11-29 | |
US201962826853P | 2019-03-29 | 2019-03-29 | |
US201962828879P | 2019-04-03 | 2019-04-03 | |
US201962839235P | 2019-04-26 | 2019-04-26 | |
US16/442,274 US10640562B2 (en) | 2018-07-17 | 2019-06-14 | T cell-antigen coupler with various construct optimizations |
US201962874426P | 2019-07-15 | 2019-07-15 | |
PCT/US2019/042297 WO2020018727A1 (en) | 2018-07-17 | 2019-07-17 | T cell-antigen coupler with various construct optimizations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202100307WA true SG11202100307WA (en) | 2021-02-25 |
Family
ID=69163917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202100307WA SG11202100307WA (en) | 2018-07-17 | 2019-07-17 | T cell-antigen coupler with various construct optimizations |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3823984A4 (he) |
JP (1) | JP7404279B2 (he) |
KR (1) | KR20210021593A (he) |
CN (1) | CN112689642A (he) |
AU (1) | AU2019307905A1 (he) |
BR (1) | BR112021000735A2 (he) |
CA (1) | CA3104887A1 (he) |
IL (1) | IL280049A (he) |
MX (1) | MX2021000541A (he) |
PH (1) | PH12021550114A1 (he) |
SG (1) | SG11202100307WA (he) |
WO (1) | WO2020018727A1 (he) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3102681B1 (en) | 2014-02-07 | 2023-10-04 | McMaster University | Trifunctional t cell-antigen coupler and methods and uses thereof |
WO2019071358A1 (en) | 2017-10-12 | 2019-04-18 | Mcmaster University | Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF |
US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
WO2022226071A1 (en) | 2021-04-21 | 2022-10-27 | Conagen Inc. | Biosynthetic production of gamma-or delta-lactones using cytochrome p450 hydroxylase enzymes or mutants thereof |
US11453723B1 (en) * | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2794658T1 (sl) * | 2011-12-19 | 2017-05-31 | Synimmune Gmbh | Bispecifična molekula protitelesa |
BR112015000638A2 (pt) * | 2012-07-13 | 2017-08-08 | Univ Pennsylvania | sequência de ácido nucleico isolada, célula, métodos para estimular uma resposta imune mediada pela célula t e uma população de célula alvo ou tecido em um mamífero, para provimento de imunidade antitumor em um mamífero, para tratamento de um mamífero que tenha uma doença, distúrbio ou condição associado com uma expressão elevada de um antígeno de tumor |
EP3102681B1 (en) * | 2014-02-07 | 2023-10-04 | McMaster University | Trifunctional t cell-antigen coupler and methods and uses thereof |
MX2017012939A (es) * | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
AU2017292936C1 (en) * | 2016-07-08 | 2024-05-02 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
EP3493827A4 (en) * | 2016-08-04 | 2020-02-26 | Memorial Sloan-Kettering Cancer Center | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY |
CN108250302A (zh) * | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | 一种多功能蛋白质 |
-
2019
- 2019-07-17 MX MX2021000541A patent/MX2021000541A/es unknown
- 2019-07-17 CA CA3104887A patent/CA3104887A1/en active Pending
- 2019-07-17 BR BR112021000735-0A patent/BR112021000735A2/pt unknown
- 2019-07-17 JP JP2020571816A patent/JP7404279B2/ja active Active
- 2019-07-17 SG SG11202100307WA patent/SG11202100307WA/en unknown
- 2019-07-17 AU AU2019307905A patent/AU2019307905A1/en active Pending
- 2019-07-17 CN CN201980047935.6A patent/CN112689642A/zh active Pending
- 2019-07-17 WO PCT/US2019/042297 patent/WO2020018727A1/en unknown
- 2019-07-17 KR KR1020217004572A patent/KR20210021593A/ko unknown
- 2019-07-17 EP EP19838648.4A patent/EP3823984A4/en active Pending
-
2021
- 2021-01-10 IL IL280049A patent/IL280049A/he unknown
- 2021-01-15 PH PH12021550114A patent/PH12021550114A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3823984A4 (en) | 2022-04-06 |
MX2021000541A (es) | 2021-08-16 |
EP3823984A1 (en) | 2021-05-26 |
PH12021550114A1 (en) | 2021-10-04 |
KR20210021593A (ko) | 2021-02-26 |
WO2020018727A1 (en) | 2020-01-23 |
JP2021530971A (ja) | 2021-11-18 |
AU2019307905A1 (en) | 2021-03-04 |
JP7404279B2 (ja) | 2023-12-25 |
CA3104887A1 (en) | 2020-01-23 |
BR112021000735A2 (pt) | 2021-07-13 |
CN112689642A (zh) | 2021-04-20 |
IL280049A (he) | 2021-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202008108SA (en) | Waveguide element | |
IL280049A (he) | מצמד תא t ואנטיגן עם אופטימיזציות מבנה מגוונות | |
CA185877S (en) | Mechanical coupler | |
GB2576486B (en) | Coupler | |
GB2577811B (en) | Connection | |
SG11202010014XA (en) | Repetition-based transmission | |
GB201800761D0 (en) | Interaction between blockchains | |
GB2576131B (en) | Coupler | |
SG10201904874XA (en) | Photodetector with sequential asymmetric-width waveguides | |
EP3664216C0 (de) | Asymmetrischer hohlleiter | |
GB201810946D0 (en) | Waveguide assembly | |
GB201805799D0 (en) | b | |
GB2580038B (en) | Coupling | |
GB2610148B (en) | Coupler | |
GB2612533B (en) | Coupler | |
EP3924631C0 (en) | CLUTCH ARRANGEMENT | |
GB2585613B (en) | Coupling | |
GB2610147B (en) | Coupler | |
GB2610146B (en) | Coupler | |
GB2576788B (en) | Cladding | |
GB201906122D0 (en) | Coupling | |
GB201818380D0 (en) | Coupling | |
GB201915109D0 (en) | Waveguides | |
ZA202004064B (en) | Coupling | |
GB201802048D0 (en) | Cladding |